prof. dr. E.M.D. (Ed) Schuuring

Education: refresher courses, post-graduate education and invited lectures (year/period, institute - evaluation period 2020-2025) (18-08-2025):

1. “Liquid biopsies: promises to improve molecular pathology and clinical practice of patients with lung cancer” Session 1: Research and Future Trends. Porto Precision Diagnostics Meeting: New frontiers in Liquid Biopsies in Cancers, Porto, Ipatimup, 16th January 2025 (invited speaker/panelist)

2.  ”Inleiding Moleculaire Pathologie”, BOP cusus Moleculaire Diagnostiek, Groningen,  23-24 januari 2025 (organisation, moderation and speaker)

3.  “Moleculaire Diagnostiek – Liquid biopsies”, BOP cusus Moleculaire Diagnostiek, Groningen, 23-24 januari 2025 (organisation, moderation and speaker)

4.  “Implementatie van ctNGS in plasma-DNA voor de detectie van mutaties in predictieve markers voor MD van NSCLC”, Netwerk Longoncologie Friesland, Leeuwarden, 28 januari 2025 (invited speaker)

5.  “CieKNT en cieBOD”, NVVP Moleculaire Dag, Utrecht, 31 januari 2025 (invited speaker)

6.  “International EQA schemes: experiences and lessons-learned from the molecular ESP lung scheme” European Masters in Molecular Pathology (EMMP), Module 9: Quality Controls, Accreditation, Regulation. 10-11 February 2025, UMCG, Groningen, The Netherlands. (invited speaker/moderator day 1)

7.  ”Molecular Tumor Board: the role in the journey towards treatment-decision-making of complex or rare variants’. Canadian Anatomic and Molecular Pathology (CAMP), European Masters in Molecular Pathology (EMMP). CAMP PODS online event. UMCG Groningen, 12th February 2025 (invited spreaker)

8.  “Comprehensive genomic profiling: the current and future needs in molecular diagnostic pathology”. Front Line Genomics 2025: Unlocking Precision Oncology’s Full Potential through Next-Gen Molecular Analysis. Webinar series: Advancing Precision Oncology through Molecular Analysis, online, 17 april 2025 (invited speaker)

9.  “The role of Molecular Tumor Boards in the journey towards treatment-decision-making of complex or rare variants: the UMCG experience” , Nordic Precision Medicine Forum 2025. Session: Advancing Molecular Tumor Boards. Stockholm, Sweden. 28-29 April 2025 (invited speaker and panelist)

10.  “Introduction: Implementing Liquid Biopsy for Precision Oncology” , Nordic Precision Medicine Forum 2025. Session: Implementing Liquid Biopsy for Precision Oncology. Stockholm, Sweden, 28 April 2025 (invited moderator for paneldiscussion)

11.  ”The development and validation of the ultraSEEK gist panel on the massarray system for monitoring and detection of primary and secondary kit mutations in plasma-derived DNA during targeted treatment of patients with gastrointestinal stromal tumors”. 14th International Symposium in Minimal Residual Cancer 2025. Liquid Biopsy from Discovery to Clinical Implementation. Session: Risk Assessment and Monitoring of Cancer Therapies. Nice, France, 8th May 2025 (invited speaker)

12.  “General introduction of Module 6: Applied Molecular Pathology in Oncology” European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 16-20 June 2025, UMCG, Groningen (speaker/moderator/course coordinator)

13.  “Introduction on the application of Molecular Pathology” European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 16-20 June 2025, UMCG, Groningen (speaker/moderator/course coordinator)

14.  “Molecular Tumor Board: the role in the journey towards treatment-decision-making of complex or rare variants” European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 16-20 June 2025, UMCG, Groningen (speaker/moderator/course coordinator)

15.  ”Molecular Tumor Boards: clinical practice”. Virtual MTB (Vincent de Jager, Jeroen Hiltermann, Arja ter Elst, Mieke Zwager, Matthew Groves, Ed Schuuring). European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 16-20 June 2025, UMCG, Groningen (participator/moderator/course coordinator)

16.  “Molecular Predictive testing in Europe, world-wide and low-income countries: how to select the most optimal predictive test”. European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 16-20 June 2025, UMCG, Groningen (participator/moderator/course coordinator)

17.  ”Carcinoma of unknown primary (PTO)” (Michel van Kruchten, Ed Schuuring). European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 16-20 June 2025, UMCG, Groningen (participator/moderator/course coordinator)

18.  “Testing for RET and NTRK fusions” European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 16-20 June 2025, UMCG, Groningen (participator/moderator/course coordinator)

19.  “European Liquid Biopsy Society” ctDNA symposium. Utrecht. 4 Juli 2025 (organiser, invited speaker)

20.  “Moleculaire Tumor Boards voor complexe tumorgenetische bevindingen en optimale behandelkeuzes”, Medical PHIT meeting 2024: Diagnostiek van de toekomst: seqeuncen verbindt laboratoria. InnStyle Maarssen, 20 maart 2024 (invited speaker)

21.  “Liquid biopsies: Moleculaire diagnostiek en klinische toepassingen van ctDNA uit bloedplasma”, Symposium nieuwe ontwikkelingen bij Hoofd-halskanker. UMCU, Utrecht, 2 April 20 maart 2024 (invited speaker)

22.  “Moleculaire Tumor Boards: de klinische praktijk van UMCG MTB”, live webinar. Precisie Oncologie Academie (POA), 23 april 2024 (organisation, invited contributor)

23.  “Monitoring clinical outcome in patients with advanced-stage non-small cell lung cancer using circulating tumor DNA”, Droplet Digital PCR World 2024 on Tour, Dubai, UAE, 7th May 2024 (invited speaker)

24.  cfDNA dag symposium. Utrecht. 14 juni 2024 (organisation)

25.  “General introduction of Module 6: Applied Molecular Pathology in Oncology” European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 17-21 June 2024, Groningen (speaker/moderator/course coordinator)

26.  “Introduction on the application of Molecular Pathology” European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 17-21 June 2024, Groningen (speaker/moderator/course coordinator)

27.  “Molecular Tumor Board: the role in the journey towards treatment-decision-making of complex or rare variants” European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 17-21 June 2024, Groningen (speaker/moderator/course coordinator)

28.  ”Molecular Tumor Boards: clinical practice”. Virtual MTB (Vincent de Jager, Anthonie van der Wekken, Arja ter Elst, Wim Timens, Matthew Groves, Ed Schuuring). European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 17-21 June 2024, Groningen (participator/moderator/course coordinator)

29.  “Molecular Predictive testing in Europe, world-wide and low-income countries: how to select the most optimal predictive test”. European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 17-21 June 2024, Groningen (participator/moderator/course coordinator)

30.  ”Carcinoma of unknown primary (PTO)” (Michel van Kruchten, Ed Schuuring). European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 17-21 June 2024, Groningen (participator/moderator/course coordinator)

31.  “Testing for RET and NTRK fusions” European Masters in Molecular Pathology (EMMP), Module 6: Applied Molecular Pathology in Oncology, 17-21 June 2024, Groningen (participator/moderator/course coordinator)

32.  “Bron data van Moleculaire Tumorboards: bestaande werkwijze UMCG-MTB”, PALGA-Farminfo cBioPortal studie 2024-2026. UMCG introductie, 14 Augustus 2024 (invited spreaker)

33.  “Toepassingen voor moleculaire diagnostiek op bloedplasma”, E-learning biomarkers module vloeibare biopten, I-O Instituut, online nascholing immuuuntherapie, september 2024, MERCK (invited speaker) [https://vimeo.com/1007698926]

34.  “Liquid biopsies in clinical practice: plasma-derived ctDNA-detection assays for early detection, diagnosis, monitoring tumor response and MRD in NSCLC”, Roche Sequencing Solutions Days 2024, GO BEYOND - together, shaping sequencing in clinical research. Mannheim, 26-27th September 2024 (invited speaker and panelist) [https://custom.cvent.com/2552253DAFF649D88BB18A3B045DC612/files/event/5670fbc7fb97412d9b77254fdd68067b/ 1e8d3f5e00b54c7ebb853b9b9e0c1b62.pdf]

35.  ”How to report plasma-derived ctDNA results to the oncologist ?” Oxford Global – Biomarkers and Precision Oncology Europe 2024. In session: Molecular Analysis, Multi-Cancer Early Detection And Testing, Companion Diagnostic Development, Basel, 30th September – 1st October 2024 (invited speaker and panelist)

36.  “De KNT-lijsten: het perspectief vanuit de pathologie”, Onco Oost - Oncologisch netwerk. Webinar Moleculaire Diagnostiek KNT-lijsten: wat mag, wat kan en wat moet ? 10 october 2024 (invited speaker)

37.  “Clinical utility of cfDNA analysis in oncology”. In Session 2: Clinical applications of cfDNA. Belgian cfDNA Oncology Meeting, Brussel, 7th November 2024 (invited speaker)

38.  Set-up of other initiatives: ELBS and COIN. In Session 4: International cfDNA working group. Belgian cfDNA Oncology Meeting, Brussel, 7th November 2024 (invited speaker)

39.  “Overview of activities: yrs 2023-2024”, ELBS General Assembly 2024. ctDNA technology working group. Barcelona Biomedical Research Park, Barcelona Spain, 26-27th November 2024 (invited speaker)

40.  “Implementatie ctDNA NGS voor diagnosed en resistentie bij MD van NSCLC”, MD Overleg MZH/UMCG, MZH, Groningen, 16 januari 2023 (invited speaker)

41.  “Regionale ontwikkelingen in de moleculaire diagnostiek: Toelichting: implementatie ctDNA NGS voor diagnosed en resistentie bij MD van NSCLC”, Netwerk Longoncologie Friesland, MCL, Leeuwarden, 17 januari 2023 (invited speaker)

42.  “Innovations in Precision Medicine require adequate molecular diagnostics: experiences of clinical practice in the Netherlands”, Masterclass on Precision Medicine for oncologists in Caribbean, 2 Februari 2023 (online) (invited speaker)

43.  “Landelijk implementatieproject NSCLC regio noord-Nederland: Werkgroep A: Plasma analyse uitbreiding in moleculaire diagnostiek”, UMCG – regio Noord Best Practice Project, 8 Feb 2023 (online) (organisatie en speaker)

44.  “Molecular diagnostics in clinical practice: how to deal with the rapid developments in Precision Medicine ?” MEB Science Day 2023 (cbg-meb.nl), Utrecht, 13th April 2023 (invited speaker)

45.  “State of the art molecular profiling to guide targeted therapies in cancer patients in clinical practice”, Matchmaking event UMCG - RUG FSE – Janssen, Groningen, 10th May 2023 (invited speaker)

46.  “Implementatie ctDNA NGS voor diagnosed en resistentie bij MD van NSCLC”, MD Overleg TREANT, Hoogeveen, 22 mei 2023 (invited speaker)

47.  cfDNA symposium. Houten, 9 juni 2023 (organiser)

48.  “Liquid biopsies: promises to improve molecular pathology and clinical practice”, Discover the World of Health Technology World 2: Future success through early detection and diagnosis. Martiniplaza, Groningen, 16 Juni 2023 (invited speaker)

49.  “Liquid Biopsies in clinical practice: Identification of therapeutically relevant mutations at baseline in plasma-derived cell free DNA in patients with metastasized NSCLC to assist in treatment decision making”, AMP Europe 2023. Industry symposium 4: Agena BioScience. Milan, Italy, 18-20 June 2023 (invited speaker)

50.  “Detection of clinically actionable mutations in NSCLC for early detection, diagnosis and monitoring tumor response using plasma-derived cell free DNA”, Nordic Oncology Forum, Stockholm, Sweden, 26-27 June 2023 (invited speaker, panelist)

51.  “The Dutch experience using predictive profiling to guide targeted therapy in cancer patients: the role of our Molecular Tumor Board”, Nordic Oncology Forum, Stockholm, Sweden, 26-27 June 2023 (moderator of session, invited speaker, panel-coordinator)

52.   “Emerging predictive biomarkers for EQA: needs and possibilities”, 35th European Congress of Pathology. Pathology – a bridge between Science and Medicine. Dublin, 9-13 September 2023 (invited speaker)

53.  “Molecular pathology at low costs: good practice and pitfalls”, 35th European Congress of Pathology. Pathology – a bridge between Science and Medicine. Dublin, 9-13 September 2023 (invited speaker)

54.  Moleculaire Dag 2023. NVVP symposium 22nd September 2023 (organisatie)

55.  Two-days Expert Workshop on Quality Assessment and Reporting. European Liquid Biopsy Society, workgroup Technical-ctDNA (Patrizio Giacomini, Ellen Heitzer, Ed Schuuring). Barcelona, Spain, 5-6 October 2023 (organisor)

56.  “Reporting of ctDNA/cfDNA data: how to get to consensus international recommendations”, European Liquid Biopsy Society, Day 2: Expert Workshop on QA and Reporting. Barcelona, Spain, 5-6 October 2023 (organisor/moderator/speaker)

57.  “Introduction to the EMMP-course Module 6 in Groningen in 2024”, Start of EMMP-course with master students. Nice, 10 October 2023 (invited speaker)

58.  “The ctDNA diagnostic landscape for MRD testing” (presentors Ellen Heitzer, Ed Schuuring, Mark Rogers), MRD GUIDE WP 2: Development of ctDNA Reference Materials and analytical benchmarking of ctDNA diagnostics for MRD assessment. MRD GUIDE annual meeting, 1st F2F meeting, CNIO, Madrid 24 October 2023

59.  “The detection of clinically actionable mutations in NSCLC for Early Detection, Diagnosis and Monitoring Tumor Response using plasma-derived Cell Free DNA”. Oxford Global -BIOMARKERS AND PRECISION ONCOLOGY EUROPE 2023, Molecular Analysis, Multi-Cancer Early Detection And Testing, Companion Diagnostic Development, Berlin, 14-15th November 2023 (invited speaker)

60.  Moleculaire Dag 2022. NVVP symposium 21st January 2022 (webinar) (organisatie en moderator)

61.  ”Inleiding Moleculaire Pathologie”, BOP cusus Moleculaire Diagnostiek, Groningen, 17-18 maart 2022 (organisation, moderation and speaker)

62.  “Moleculaire Diagnostiek – Liquid biopsies”, BOP cusus Moleculaire Diagnostiek, Groningen, 17-18 maart 2022 (organisation, moderation and speaker)

63. ”The first nation-wide COIN-EQA program on cell-free DNA extraction methods from liquid biopsies by Dutch COIN consortium”, The European Liquid Biopsy Society - First ELBS ctDNA Technology Meeting, 23rd March 2022 (online) (organisation, moderation and speaker)

64.  ”Precision Medicine: Comprehensive Genomic Profiling to guide targeted therapy in patients with lung cancer in clinical practice”, FHI Meeting 2023, Leiden, 5th April 2022 (invited speaker)

65.  Treatment monitoring with the UltraSEEK® Lung Panel”, Agena Bioscience Oncology Scientific Advisory Board (SAB), Virtual Kick-off Meeting, 21st April 2022 (invited speaker)

66.  The Dutch experience using Comprehensive Genomic Profiling to guide targeted therapy in cancer patients: Molecular Tumor Board”, Nordic Precision Medicine Forum 2022, Stockholm, 29th April 2022 (online) (invited speaker)

67.  “Circulating tumor DNA as a monitoring tool for clinical outcome in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors”, 2022 ddPCR Global Symposium Bio-Rad, 25th May 2022 (webinar) (invited speaker)

68.  ”Hoe kunnen we moleculaire diagnostiek in de regio optimaliseren ? De moleculaire diagnostiek van longkanker”, E-learning “Belangrijke wijzigingen in de NSCLC-richtlijn” en “De moleculaire diagnostiek van longkanker”, Discussieavond Groningen-Hoogkerk, 11 mei 2022 (organisatie en speaker)

69.  “Detection of clinically actionable mutations in NSCLC: is there a one-fits-all cell-free ctDNA test for routine clinical practice ?”, The 10th Santorini Conference, SESSION I – LIQUID BIOPSY, PAST, PRESENT, FUTURE, Santorini, Greece, 23-26 May 2022 (invited speaker)

70.  “De implementatie van plasma ctDNA testing in onze MD: zijn we er klaar voor ?”, Gastcollege Hanze Hogeschool, Moleculaire diagnostiek van longkanker, Groningen, 3 juni 2022 (invited speaker)

71.  “Detection of clinically actionable mutations in NSCLC: is there a one-fits-all cell-free ctDNA test for routine clinical practice ?”, Liquid Biopsy Forum, Curtis&Wyss, 9-10th June 2022 (online meeting) (invited speaker)

72.  “Circulating tumor DNA as a monitoring tool for clinical outcome in patients with advanced stage non-small cell lung cancer treated with immune checkpoint inhibitors”, EACR 2022 Congress, Innovative Cancer Science: Translating Biology to Medicine, Bio-RAD Symposium “a new dimension in multplexing with Droplet Digital PCR”, 20th June 2022, Sevilla, Spain (invited speaker)

73.  “Moleculaire diagnostiek ontwikkelingen bij (long)kanker in era Harry Groen”, Afscheidssymposium voor prof dr H.J.M. (Harry) Groen, UMCG, Groningen, 22 juni 2022 (invited speaker)

74.  “ctDNA reference materials”, The European Liquid Biopsy Society – The 2nd ELBS ctDNA Technology Meeting, 5th July 2022 (online) (organisation and moderation)

75.  “MD ontwikkelingen UMCG en regio-Noord: de diagnostiek van primaire tumor onbekend (PTO/CUP)”, MD-werkoverleg, Pathologie -MZH, 12 juli 2022 (speaker)

76.  “Experiences and lessons-learned from the molecular ESP lung scheme”, 34th European Congress of Pathology, SPEC-06 - Special Session ESP QA: Good results come from experience, experience comes from bad results, Basel, 6th September 2022 (invited speaker)

77.  “De rol van liquid biopsies bij vroege stadia en MRD”, 15e avondsymposium Thoracale oncologie in Noordoost Nederland “waar staan we nu?”, Hoogkerk, 5 oktober 2022 (invited speaker)

78.  “Moleculaire Tumorboards: Hoe en waarom ?”, Precisie Oncologie Academie (POA), Webinar, 10 oktober 2022 (invited speaker)

79.  “The Dutch experience using predictive profiling to guide targeted therapy in cancer patients: The role of our Molecular Tumor Board”, PMNET Precision Medicine Networking Forum, Riga, Latvia, 13-14 October 2022 (invited speaker)

80.  “Detection of clinically actionable mutations in NSCLC: is there a One-Fits-All Cell-Free ctDNA test for routine clinical practice?”, Oxford Global - NextGen Omics UK: “Integrating Digital PCR with Further Technologies; NGS, Genome Editing and Novel Digital PCR Systems”, London, 9-10th November 2022 (online) (invited speaker)

81.  ”Inleiding Moleculaire Pathologie”, BOP cusus Moleculaire Diagnostiek, Groningen, 10-11 November 2022 (organisation, moderation and speaker)

82.  “Moleculaire Diagnostiek – Liquid biopsies”, BOP cusus Moleculaire Diagnostiek, Groningen, 10-11 November 2022 (organisation, moderation and speaker)

83.  “Circulating tumor DNA as a monitoring tool for clinical outcome in patients with advanced-stage non-small cell lung cancer treated with immune checkpoint  inhibitors”, 1st Annual EEMEA Meeting Istanbul, Droplet Digital PCR Symposium, 23rd November 2022, Istanbul, Turkey (invited speaker)

84.  “Oncology: Tumor and Liquid Biopsy applications”, Agena Biosciences Clinical User Group Meeting 2022, Hamburg, 1-2 December 2022 (invited speaker)

85.  “MD ontwikkelingen”, Refereren met Pathologen, Pathologie Friesland, Leeuwarden, 15 december 2023 (invited speaker)

86.  Implementation of Molecular Tumorboards in Clinical Practice. Roche virtual experience sharing event, 28^th January 2021(webinar/workshop) (invited panelist)

87.  Moleculaire Dag 2021. NVVP symposium 29th January 2021 (webinar) (organisatie en moderator)

88.  “RET diagnostiek in het lab”. Webcast: Update aanpak RET-gedreven tumoren; diagnostiek en behandelopties. A Lilly-sponsored RET-event. 10^th March 2021 (invited speaker and panelist) [https://www.mednet.nl/webcast/update-aanpak-ret-gedreven-tumoren-diagnostiek-en-behandelopties/]

89.  “Circulating tumor DNA as an early on-treatment predictive biomarker for patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors”. Front Line Genomics: Applications of dPCR in liquid biopsy and cancer monitoring. 18th March 2021 (webinar) (invited speaker) [https://frontlinegenomics.com/next-gen-pcr-online/]

90.  “NTRK diagnostiek in het lab” Gast-college, Hanze Hogeschool Groningen, 9 juni 2021 (invited speaker)

91.  ”Plaats van de moleculaire tumor board (MTB) in het zorgsysteem”. Predictive Analysis for THerapy: PATH to optimising access to personalised cancer therapy in the Netherlands. Symposium PATH 8 sept 2021 (invited speaker) [https://us3.campaign-archive.com/?e=[UNIQID]&u=fce67ea45d2705ea1f2aa78b9&id=0a3310fac9]

92.  Roche Dialogue over de toekomst van genetische testen bij kanker, ronde tafel discussie (Warnyta Minnaard, Leonie Sazias, Ed Schuuring, Wendy Maas), Nieuwspoort 13 Sept 2021 (invited panelist) [https://www.roche.nl/nl/Waar-werken-we-aan/Innovatie/rochedialogues.html] [https://www.qruxx.com/naar-een-heel-nieuw-systeem-voor-kankerzorg-en-diagnostiek/]

93.  “Dealing with complexity through Comprehensive Genomic Profiling”. Illumina Satellite Meeting at Annual ESMO meeting 2021: Profiling Non-Small Cell Lung Cancer using Comprehensive Genomic Profiling, 17th September 2021 (online) (invited speaker) [https://emea.illumina.com/company/news-center/feature-articles/at-esmo-focus-on-non-small-cell-lung-cancer.html]

94.  “Detection of therapeutically targetable mutations in NSCLC: Is there a one size fits all cell free DNA test ?”. CAP TODAY webinar. 13th October 2021 (invited speaker) [https://www.captodayonline.com/detection-of-therapeutically-targetable-mutations-in-nsclc-is-there-a-one-size-fits-all-cell-free-dna-test/]

95.  ”Testing for RET in NSCLC”. Lilly Virtual Satellite Symposium at the International Lung Cancer Summit 2021. Precision Oncology: Focus on RET-driven NSCLC. 13th October 2021 (invited speaker/panelist) [https://www.lungcancersummit.org/wp-content/uploads/2021/10/ILCS-Virtual-Symposium_13-October-2021_Flyer_V2.pdf]

96.  ”Liquid biopsies in lung: Predictive markers in NSLC, monitoring, screening and resistance mutation testing: is there a one-size-fits-all cell free DNA test ?”. Biocartis User Meeting. Amsterdam. 28-29th October 2021 (invited speaker)

97.  ”Het gebruik van tumorweefsel of bloedplasma: is er ruimte voor Liquid Biopsy ?”. Nascholing: Huidige status NSCLC Behandeling en Diagnostiek . De moleculaire diagnostiek van longkanker (e-learning; Module B). 4 October 2021 (invited speaker, organization committee)

98.  “Circulating tumor DNA as a monitoring tool for clinical outcome in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors” Oxford Global: NextGen Omics UK. 3rd Annual Digital PCR Congress, 4-5th November 2021 London. Webinar (meeting advisory board and invited speaker)

99.  “Circulating tumor DNA as an early on-treatment predictive biomarker for patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors”, Festival of Biologics, World Immunotherapy Congress, 9-11^th November 2021, Basel (invited speaker)

100.  ”ALK mutatieanalyse met behandelconsequentie”. Expertisegroep Longpathologie. NVVP Pathologendagen. 18-19 November 2021 (webinar) (invited speaker)

101.  ”Summary of survey questions: efforts for harmonization by Dutch COIN consortium”. The European Liquid Biopsy Society ctDNA Technology Meeting. 6 December 2021 (invited speaker; online)

102.  “Circulating tumor DNA as an early on-treatment predictive biomarker for patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors”. Global Engage: the Research & Technology Series: qPCR & Digital PCR / Liquid Biopsies / Flow Cytometry. London, 6-7 December 2021 (invited speaker)

103.  Circulating tumor DNA as a molecular blood-borne biomarker to predict tumor response in lung cancer patients treated with immunotherapy. Session „Immunoliquid Biopsy“. Simposium Liquid Biopsy 2020.  23-25 January 2020, Santiago de Compostela, Spain (invited speaker) [https://simposiobiopsialiquida.com/wp-content/uploads/2020/01/January-Friday-24th_Improving-the-protocols_Dr.Ed-Schuuring.pdf]

104.  “Implementatie PIK3CA testing in NL: Diagnostiek bij gemetastaseerde borstkanker. Wat is de huidige stand van zaken en hoe richten we de PIK3CA bepaling in in NL? Perspectief van de KMBPer” Novartis Pharma Advisory Board, 12 Februari 2020, Utrecht (organiser/speaker)

105.  “Circulating tumor DNA to monitor tumor response in lung cancer patients treated with immunotherapy” 5th Asia Pacific ddPCR Symposium BioRAD 2020. May 27, 2020 (webinar) [https://info.bio-rad.com/AP_ddPCR-Symposium-2020.html?WT.mc_id=200424028087#Liquid Biopsy] (invited speaker)

106.  “Molecular diagnostics for optimal therapy management in lung cancer: ALK testing methods, guidelines and quality assessment” Roche Symposium 2020. The Institute Oncology Days, Romania, 27th August 2020 (webinar) (invited speaker)

107.  “Prediction of tumor response in NSCLC patients treated with immunotherapy by monitoring of ctDNA levels” Global Engage “Research and Technology series: qPCR & digital PCR. 8-9th October 2020 (webinar) (invited speaker)

108.  “Cell-free circulating DNA: Preanalytical considerations and detection of clinical-relevant mutations in NSCLC eligible for targeted therapy using UltraSEEK UltraSEEK® Lung test on MassARRAY® system” Agena Webinar:  A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC. 15th October 2020 (webinar) (invited speaker)

109.  “Detection of clinical-relevant mutations in NSCLC eligible for targeted therapy using circulating tumor DNA in cell free plasma” Seracare Webinar: The promise of Liquid Biopsy for cancer diagnostics and therapeutic monitoring: are we there yet? 27th October 2020 (webinar) (invited speaker/panel-member)

110.  “A comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC” Agena Berlin Seminar: Precision Molecular Analysis, Examples in oncology. 3rd November 2020 (invited speaker)

111.  “Monitoring circulating tumor DNA as a molecular bloodborne-based biomarker to predict tumor response in lung cancer patients treated with immunotherapy” Festival of Biologics: World Immunotherapy Congress 2020. Biomarkers in Immunotherapy. 4^th November 2020 (Virtual) (invited speaker)

112.  “Prediction of tumor response in NSCLC patients treated with immunotherapy by monitoring of ctDNA levels” NextGen Omics Series UK. Global Engage “2nd Annual Digital PCR Congress: dPCR technologies. 6-8th November 2020 (Virtual) (invited speaker)

113.  Pathologieforum 2020: Ontwikkelingen in de longoncologie (prof dr E Schuuring, prof dr S Willems, dr J von der Thüsen, dr N Claessens). MedTalks Virtual meeting Oct 2020 (organizer and panel member) (www.medtalks.nl/pathologie2020-long?utm_source=MEDtalks+NL&utm_campaign=67d245f3c4-nsclc2020&utm_medium=email&utm_term=0_aad2765d2c-67d245f3c4-356136050)

114.  “A comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC”. Vancouver virtual AMP 2020 Workshop (Agena): Disease detection and monitoring with targeted, sensitive and cost-effective liquid biopsy panels. 17^th November 2020 (webinar) (invited speaker)